A detailed history of Texas Permanent School Fund transactions in Abb Vie Inc. stock. As of the latest transaction made, Texas Permanent School Fund holds 292,616 shares of ABBV stock, worth $57.6 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares
292,616
Previous 364,872 19.8%
Holding current value
$57.6 Million
Previous $66.4 Million 24.46%
% of portfolio
0.45%
Previous 0.53%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$154.79 - $180.76 $11.2 Million - $13.1 Million
-72,256 Reduced 19.8%
292,616 $50.2 Million
Q1 2024

May 03, 2024

BUY
$159.82 - $182.1 $67,603 - $77,028
423 Added 0.12%
364,872 $66.4 Million
Q4 2023

Feb 08, 2024

SELL
$137.6 - $154.97 $23,667 - $26,654
-172 Reduced 0.05%
364,449 $56.5 Million
Q3 2023

Nov 09, 2023

SELL
$133.59 - $154.65 $648,445 - $750,671
-4,854 Reduced 1.31%
364,621 $54.4 Million
Q2 2023

Aug 07, 2023

BUY
$132.51 - $164.9 $155,964 - $194,087
1,177 Added 0.32%
369,475 $49.8 Million
Q1 2023

May 01, 2023

BUY
$144.61 - $166.54 $16.9 Million - $19.5 Million
117,032 Added 46.58%
368,298 $58.7 Million
Q4 2022

Feb 07, 2023

BUY
$138.31 - $165.87 $151,034 - $181,130
1,092 Added 0.44%
251,266 $40.6 Million
Q3 2022

Oct 25, 2022

BUY
$134.21 - $153.93 $2.25 Million - $2.58 Million
16,765 Added 7.18%
250,174 $33.6 Million
Q2 2022

Aug 08, 2022

BUY
$137.62 - $174.96 $564,242 - $717,336
4,100 Added 1.79%
233,409 $35.7 Million
Q1 2022

May 06, 2022

SELL
$131.98 - $163.75 $1.87 Million - $2.32 Million
-14,179 Reduced 5.82%
229,309 $37.2 Million
Q4 2021

Feb 08, 2022

SELL
$107.43 - $135.93 $3.17 Million - $4.01 Million
-29,510 Reduced 10.81%
243,488 $33 Million
Q3 2021

Oct 28, 2021

SELL
$106.4 - $120.78 $2.17 Million - $2.47 Million
-20,420 Reduced 6.96%
272,998 $29.4 Million
Q2 2021

Jul 27, 2021

SELL
$105.21 - $117.21 $152,344 - $169,720
-1,448 Reduced 0.49%
293,418 $33.1 Million
Q1 2021

May 03, 2021

SELL
$102.3 - $112.62 $1.68 Million - $1.85 Million
-16,409 Reduced 5.27%
294,866 $31.9 Million
Q4 2020

Feb 04, 2021

SELL
$80.49 - $108.67 $1.65 Million - $2.23 Million
-20,514 Reduced 6.18%
311,275 $33.4 Million
Q3 2020

Nov 06, 2020

BUY
$85.91 - $100.83 $1.83 Million - $2.14 Million
21,244 Added 6.84%
331,789 $29.1 Million
Q2 2020

Aug 04, 2020

BUY
$73.37 - $98.18 $3.89 Million - $5.2 Million
53,006 Added 20.58%
310,545 $30.5 Million
Q1 2020

Apr 27, 2020

SELL
$64.5 - $97.79 $266,643 - $404,263
-4,134 Reduced 1.58%
257,539 $19.6 Million
Q4 2019

Feb 03, 2020

SELL
$72.13 - $90.25 $990,344 - $1.24 Million
-13,730 Reduced 4.99%
261,673 $23.2 Million
Q3 2019

Oct 31, 2019

SELL
$62.98 - $75.72 $610,528 - $734,029
-9,694 Reduced 3.4%
275,403 $20.9 Million
Q2 2019

Aug 09, 2019

SELL
$65.7 - $83.98 $122,924 - $157,126
-1,871 Reduced 0.65%
285,097 $20.7 Million
Q1 2019

May 02, 2019

SELL
$77.14 - $90.79 $1.2 Million - $1.41 Million
-15,585 Reduced 5.15%
286,968 $23.1 Million
Q4 2018

Feb 11, 2019

SELL
$77.85 - $96.01 $2.91 Million - $3.59 Million
-37,384 Reduced 11.0%
302,553 $27.9 Million
Q3 2018

Oct 22, 2018

SELL
$88.91 - $98.84 $2.66 Million - $2.95 Million
-29,876 Reduced 8.08%
339,937 $32.2 Million
Q2 2018

Jul 23, 2018

SELL
$89.78 - $106.23 $3.78 Million - $4.47 Million
-42,067 Reduced 10.21%
369,813 $34.3 Million
Q1 2018

Apr 20, 2018

SELL
$92.01 - $123.21 $2.14 Million - $2.87 Million
-23,292 Reduced 5.35%
411,880 $39 Million
Q4 2017

Jan 23, 2018

SELL
$89.56 - $98.21 $591,096 - $648,186
-6,600 Reduced 1.49%
435,172 $42.1 Million
Q3 2017

Nov 13, 2017

BUY
$69.85 - $89.22 $30.9 Million - $39.4 Million
441,772
441,772 $39.3 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $348B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Texas Permanent School Fund Portfolio

Follow Texas Permanent School Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

News

Stay updated on Texas Permanent School Fund with notifications on news.